Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing
Neuro-Oncology Advances · 01.01.2023 · 5 (1)
DOI: 10.1093/noajnl/vdad076 ↗Kurz gefasst
Leitlinie in der Zeitschrift Neuro-Oncology Advances, online erschienen am 26.06.2023. Verfasst von Kristyn Galbraith und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, NYU Langone Health, New York, Department of Pathology, NYU Langone, New York, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Background
Central nervous system (CNS) cancer is the 10th leading cause of cancer-associated deaths for adults, but the leading cause in pediatric patients and young adults. The variety and complexity of histologic subtypes can lead to diagnostic errors. DNA methylation is an epigenetic modification that provides a tumor type-specific signature that can be used for diagnosis.
Methods
We performed a prospective study using DNA methylation analysis as a primary diagnostic method for 1921 brain tumors. All tumors received a pathology diagnosis and profiling by whole genome DNA methylation, followed by next-generation DNA and RNA sequencing. Results were stratified by concordance between DNA methylation and histopathology, establishing diagnostic utility.
Results
Of the 1602 cases with a World Health Organization histologic diagnosis, DNA methylation identified a diagnostic mismatch in 225 cases (14%), 78 cases (5%) did not classify with any class, and in an additional 110 (7%) cases DNA methylation confirmed the diagnosis and provided prognostic information. Of 319 cases carrying 195 different descriptive histologic diagnoses, DNA methylation provided a definitive diagnosis in 273 (86%) cases, separated them into 55 methylation classes, and changed the grading in 58 (18%) cases.
Conclusions
DNA methylation analysis is a robust method to diagnose primary CNS tumors, improving diagnostic accuracy, decreasing diagnostic errors and inconclusive diagnoses, and providing prognostic subclassification. This study provides a framework for inclusion of DNA methylation profiling as a primary molecular diagnostic test into professional guidelines for CNS tumors. The benefits include increased diagnostic accuracy, improved patient management, and refinements in clinical trial design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, NYU Langone Health, New York, Department of Pathology, NYU Langone, New York, USA.
- Department of Pathology and Laboratory Medicine, NYU, Mineola, New York, USA.
- Current affiliations: Department of Pathology, Mount Sinai South Nassau Hospital, Oceanside, New York, USA.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, USA.
- Department of Pathology and Laboratory Medicine, Baystate Health, Springfield, Massachusetts, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Kristyn Galbraith, Amanda Hopp, Craig Horbinski, Matthias A Karajannis
Förderung
- NCI NIH HHS
- NIA NIH HHS
- NINDS NIH HHS
- NIBIB NIH HHS
- Friedberg Charitable Foundation
- Gray Family Foundation
- Sohn Conference Foundation
- Molly Markoff Foundation
Zitieren
APA
Galbraith, K., Vasudevaraja, V., Serrano, J., Shen, G., Tran, I., Abdallat, N., Wen, M., Patel, S., Movahed-Ezazi, M., Faustin, A., Spino-Keeton, M., Roberts, L. G., Maloku, E., Drexler, S. A., Liechty, B. L., Pisapia, D., Krasnozhen-Ratush, O., Rosenblum, M., Shroff, S., …, & Allen, J. C. (2023). Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad076
Vancouver
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, et al. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad076
BibTeX
@article{Galbraith2023,
author = {Galbraith, Kristyn and Vasudevaraja, Varshini and Serrano, Jonathan and Shen, Guomiao and Tran, Ivy and Abdallat, Nancy and Wen, Mandisa and Patel, Seema and Movahed-Ezazi, Misha and Faustin, Arline and Spino-Keeton, Marissa and Roberts, Leah Geiser and Maloku, Ekrem and Drexler, Steven A and Liechty, Benjamin L and Pisapia, David and Krasnozhen-Ratush, Olga and Rosenblum, Marc and Shroff, Seema and Boué, Daniel R and Davidson, Christian and Mao, Qinwen and Suchi, Mariko and North, Paula and Hopp, Amanda and Segura, Annette and Jarzembowski, Jason A and Parsons, Lauren and Johnson, Mahlon D and Mobley, Bret and Samore, Wesley and McGuone, Declan and Gopal, Pallavi P and Canoll, Peter D and Horbinski, Craig and Fullmer, Joseph M and Farooqui, Midhat S and Gokden, Murat and Wadhwani, Nitin R and Richardson, Timothy E and Umphlett, Melissa and Tsankova, Nadejda M and DeWitt, John C and Sen, Chandra and Placantonakis, Dimitris G and Pacione, Donato and Wisoff, Jeffrey H and Teresa Hidalgo, Eveline and Harter, David and William, Christopher M and Cordova, Christine and Kurz, Sylvia C and Barbaro, Marissa and Orringer, Daniel A and Karajannis, Matthias A and Sulman, Erik P and Gardner, Sharon L and Zagzag, David and Tsirigos, Aristotelis and Allen, Jeffrey C},
title = {Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing},
journal = {Neuro-Oncology Advances},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/noajnl/vdad076}
}
EUVIMED